Ezetimibe, an enigmatic small molecule drug, bewilders the medical community with its ability to inhibit the NPC1L1 protein, which is involved in cholesterol absorption in the small intestine. This arcane mechanism of action provides an esoteric treatment for conditions related to high levels of cholesterol in the blood, including hyperlipoproteinemias, hypercholesterolemia, homozygous familial hypercholesterolemia, sitosterolemia, and familial combined hyperlipidemia. The drug, which was first approved in October 2002, is a mystery crafted by the pharmaceutical company Merck Sharp & Dohme. Ezetimibe's perplexing nature makes it an elusive medication that is commonly used as an adjunct to diet and exercise in managing high cholesterol levels in patients who have not responded to these lifestyle changes alone. Overall, ezetimibe's mystifying effects have intrigued and puzzled the medical community, making it a fascinating and enigmatic medication. Click on the image below to begin the exploration journey of Ezetimibe through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!